New Approaches in Detection and Treatment of Familial Hypercholesterolemia

por Hartgers, Merel L., Ray, Kausik K., Hovingh, G. Kees
Publicado 2015

The clinical applicability of polygenic risk scores for LDL-cholesterol: considerations, current evidence and future perspectives

por Cupido, Arjen J., Tromp, Tycho R., Hovingh, G. Kees
Publicado 2021

Angiopoietin-like 3 inhibition and the liver: less is more?

por Oostveen, Reindert F., Hovingh, G. Kees, Stroes, Erik S.G.
Publicado 2023

Retrospective analysis of cohort database: Phenotypic variability in a large dataset of patients confirmed to have homozygous familial hypercholesterolemia

por Raal, Frederick J., Sjouke, Barbara, Hovingh, G. Kees, Isaac, Barton F.
Publicado 2016

The potential of glucagon-like peptide-1 receptor agonists in heart failure

por Kreiner, Frederik Flindt, Hovingh, G. Kees Kornelis, von Scholten, Bernt Johan
Publicado 2022

Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors

por Pećin, Ivan, Hartgers, Merel L, Hovingh, G Kees, Dent, Ricardo, Reiner, Željko
Publicado 2017

The iterative lipid impact on inflammation in atherosclerosis

por Kraaijenhof, Jordan M., Hovingh, G. Kees, Stroes, Erik S.G., Kroon, Jeffrey
Publicado 2021

Low‐Density Lipoprotein Cholesterol Attributable Cardiovascular Disease Risk Is Sex Specific

por Cupido, Arjen J., Asselbergs, Folkert W., Schmidt, A. Floriaan, Hovingh, G. Kees
Publicado 2022

High-Density Lipoprotein (HDL) Particle Subpopulations in Heterozygous Cholesteryl Ester Transfer Protein (CETP) Deficiency: Maintenance of Antioxidative Activity

por Chantepie, Sandrine, Bochem, Andrea E., Chapman, M. John, Hovingh, G. Kees, Kontush, Anatol
Publicado 2012

Genetic evidence implicating natriuretic peptide receptor-3 in cardiovascular disease risk: a Mendelian randomization study

por Cronjé, Héléne T., Karhunen, Ville, Hovingh, G. Kees, Coppieters, Ken, Lagerstedt, Jens O., Nyberg, Michael, Gill, Dipender
Publicado 2023

Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials

por Bays, Harold E., Rosenson, Robert S., Baccara-Dinet, Marie T., Louie, Michael J., Thompson, Desmond, Hovingh, G. Kees
Publicado 2018

Genetically Predicted Neutrophil-to-Lymphocyte Ratio and Coronary Artery Disease: Evidence From Mendelian Randomization

por Cupido, Arjen J., Kraaijenhof, Jordan M., Burgess, Stephen, Asselbergs, Folkert W., Hovingh, G. Kees, Gill, Dipender
Publicado 2022

Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study

por Langslet, Gisle, Hovingh, G. Kees, Guyton, John R., Baccara-Dinet, Marie T., Letierce, Alexia, Manvelian, Garen, Farnier, Michel
Publicado 2020

LDL-C calculated by Friedewald, Martin-Hopkins, or NIH equation 2 versus beta-quantification: pooled alirocumab trials

por Ginsberg, Henry N., Rosenson, Robert S., Hovingh, G. Kees, Letierce, Alexia, Samuel, Rita, Poulouin, Yann, Cannon, Christopher P.
Publicado 2021

Dissecting the IL‐6 pathway in cardiometabolic disease: A Mendelian randomization study on both IL6 and IL6R

por Cupido, Arjen J., Asselbergs, Folkert W., Natarajan, Pradeep, Ridker, Paul M., Hovingh, G. Kees, Schmidt, A. Floriaan
Publicado 2022

Filter-based hybridization capture of subgenomes enables resequencing and copy-number detection

por Herman, Daniel S, Hovingh, G Kees, Iartchouk, Oleg, Rehm, Heidi L, Kucherlapati, Raju, Seidman, J G, Seidman, Christine E
Publicado 2009

Atorvastatin Has a Dose‐Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double‐Blind Randomized Controlled Trials

por Vogt, Liffert, Bangalore, Sripal, Fayyad, Rana, Melamed, Shari, Hovingh, G. Kees, DeMicco, David A., Waters, David D.
Publicado 2019

Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: The EPIC-Norfolk prospective population study

por Perrot, Nicolas, Verbeek, Rutger, Sandhu, Manjinder, Boekholdt, S. Matthijs, Hovingh, G. Kees, Wareham, Nicholas J., Khaw, Kay-Tee, Arsenault, Benoit J.
Publicado 2017

Effects of Supra-Physiological Levothyroxine Dosages on Liver Parameters, Lipids and Lipoproteins in Healthy Volunteers: A Randomized Controlled Crossover Study

por Sjouke, Barbara, Elbers, Laura P. B., van Zaane, Bregje, Kastelein, John J. P., Hovingh, G. Kees, Gerdes, Victor E. A.
Publicado 2017

Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study

por Kastelein, John J.P., Nissen, Steven E., Rader, Daniel J., Hovingh, G. Kees, Wang, Ming-Dauh, Shen, Tong, Krueger, Kathryn A.
Publicado 2016